Effect of Dehydroepiandrosterone on Neurotransmitter Levels and Appetite Regulation of the Obese Zucker Rat: The Obesity Research Program
Jude Abadie, Bruce E. Wright, Gonzalo Correa, Elizabeth Browne, Johnny R. Porter, Frank Svec
Diabetes, Vol. 42, Issue 5, pp. 662–669 (1993)
10.2337/diab.42.5.662
PMID: 7683287
Abstract
The obese Zucker rat is a model of youth-onset obesity associated with hyperphagia. In this study, dehydroepiandrosterone's effect at decreasing food intake and body weight in the obese Zucker rat was investigated. Rats were treated with a dehydroepiandrosterone-supplemented diet (0.0, 0.06, 0.15, 0.3, or 0.6%) for 7 days. The 0.3 and 0.6% treatment groups showed a dramatic decrease in daily food intake, which was evident the 1st day. In addition to the reduction in food intake, body weight changes also were affected significantly in the high-dose treatment groups. The possibility that these dehydroepiandrosterone-induced changes were correlated to perturbations in central neurotransmitter levels associated with appetite control was investigated. The hypothalamus, frontal cortex, striatum, and hippocampus of dehydroepiandrosterone-treated animals were assayed for neurotransmitters known to have inhibitory or stimulatory effects on feeding behavior (serotonin, dopamine, norepinephrine, and epinephrine). Significant differences from steroid-free controls were noted only in the levels of hypothalamic serotonin in animals treated with dehydroepiandrosterone. Serotonin in the hypothalamus has been shown to decrease feeding behavior. The magnitude of dehydroepiandrosterone's effect on hypothalamic serotonin correlated with its effect on feeding behavior. Thus, dehydroepiandrosterone may reduce hyperphagia by altering hypothalamic levels of serotonin.
Topics
Field: Medicine · Subfield: Endocrinology, Diabetes and Metabolism
Keywords
Endocrinology,Internal medicine,Dehydroepiandrosterone,Serotonin,Appetite,Neurotransmitter,Hypothalamus,Norepinephrine,Dexfenfluramine,Medicine
MeSH Terms
UN Sustainable Development Goals
- Zero hunger (0.57)
All Available Versions
- Landing page — Diabetes publishedVersion
- Landing page — PubMed publishedVersion
Citations by Year
| 2024 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|
| 2 | 1 | 2 | 1 | 2 | 2 | 3 | 5 | 1 | 2 |
- Role of Insulin Resistance in Human Disease 1988 · 12181
- Metabolic Endotoxemia Initiates Obesity and Insulin Resistance 2007 · 6634
- The Pathobiology of Diabetic Complications 2005 · 5350
- Classification and Diagnosis of Diabetes Mellitus and Other Categories of Glucose Intolerance 1979 · 4954
- Changes in Gut Microbiota Control Metabolic Endotoxemia-Induced Inflammation in High-Fat Diet–Induced Obesity and Diabetes in Mice 2008 · 4808
- A monoclonal gammopathy precedes multiple myeloma in most patients 2009 · 571
- Patterns of monoclonal immunoglobulins and serum free light chains are significantly different in black compared to white monoclonal gammopathy of undetermined significance (MGUS) patients 2011 · 48
- Are Renal Reference Intervals Required When Screening for Plasma Cell Disorders With Serum Free Light Chains and Serum Protein Electrophoresis? 2009 · 48
- Assessment of serum free light chain assays for plasma cell disorder screening in a Veterans Affairs population. 2006 · 43
- Albumin cobalt binding assay to rule out acute coronary syndrome. 2005 · 42
Continue on JournalsHub
Put what you just read into practice with these free tools.